Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BBIO

BridgeBio Pharma Inc

Sep 12 • 04:00PM ET

51.21

-1.39 -2.64 %

Healthcare • Biotechnology • USA • NASD

Peers: VRTX BMRN BLUE CRSP NBIX SRPT ALNY RARE PRTA FOLD

| Held by: VTI IWM VB XBI VBK VXF IWO IBB SCHA VTWO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-4.09	Insider Own	15.18%	Shs Outstand	191.16M	Perf Week	-4.07%
Market Cap	9.79B	Forward P/E	-	EPS next Y	-1.82	Insider Trans	-26.97%	Shs Float	162.16M	Perf Month	1.65%
Enterprise Value	11.72B	PEG	-	EPS next Q	-0.86	Inst Own	89.31%	Short Float	12.28%	Perf Quarter	29.16%
Income	-776.41M	P/S	41.52	EPS this Y	-21.87%	Inst Trans	3.57%	Short Ratio	6.98	Perf Half Y	58.50%
Sales	235.81M	P/B	-	EPS next Y	48.19%	ROA	-82.84%	Short Interest	19.91M	Perf YTD	86.63%
Book/sh	-9.35	P/C	12.93	EPS next 5Y	-	ROE	-	52W High	54.60 -6.21%	Perf Year	70.76%
Cash/sh	3.96	P/FCF	-	EPS past 3/5Y	9.60% -3.04%	ROIC	-88.26%	52W Low	21.72 135.77%	Perf 3Y	381.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	47.10% 40.48%	Gross Margin	94.79%	Volatility	4.01% 4.13%	Perf 5Y	77.07%
Dividend TTM	-	EV/Sales	49.70	EPS Y/Y TTM	-55.29%	Oper. Margin	-273.84%	ATR (14)	2.10	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.08	Sales Y/Y TTM	7.62%	Profit Margin	-329.25%	RSI (14)	52.92	Recom	1.29
Dividend Gr. 3/5Y	- -	Current Ratio	5.19	EPS Q/Q	-143.82%	SMA20	0.50%	Beta	1.37	Target Price	66.39
Payout	-	Debt/Eq	-	Sales Q/Q	4999.86%	SMA50	5.83%	Rel Volume	0.73	Prev Close	52.60
Employees	730	LT Debt/Eq	-	Earnings	Aug 05 AMC	SMA200	36.65%	Avg Volume	2.85M	Price	51.21
IPO	Jun 27, 2019	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.74% 25.66%	Trades		Volume	2,087,695	Change	-2.64%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-30-25	Resumed	Raymond James	Outperform	$56
Jul-21-25	Initiated	Truist	Buy	$66
Jul-14-25	Initiated	Jefferies	Buy	$70
Jul-09-25	Upgrade	Oppenheimer	Perform → Outperform	$60
Jun-17-25	Initiated	Wolfe Research	Outperform	$49
Mar-31-25	Initiated	Redburn Atlantic	Buy	$50
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Oct-03-24	Initiated	Oppenheimer	Perform
Sep-04-24	Initiated	Piper Sandler	Overweight	$46
Mar-21-24	Resumed	Raymond James	Outperform	$45
Jan-31-24	Initiated	BMO Capital Markets	Market Perform	$37
Dec-08-23	Initiated	Wells Fargo	Overweight	$58
Dec-08-23	Initiated	Wells Fargo	Overweight
Nov-07-23	Initiated	Citigroup	Buy	$42
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$50
Jul-18-23	Downgrade	Jefferies	Buy → Hold	$24 → $33
Apr-19-23	Initiated	Evercore ISI	Outperform	$40
Feb-06-23	Initiated	Cowen	Outperform
Dec-27-21	Reiterated	SVB Leerink	Outperform	$66 → $24
Dec-27-21	Reiterated	Mizuho	Buy	$86 → $25

Show Previous Ratings

Sep-10-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-08-25 10:15AM	Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth? (Zacks)
Sep-06-25 02:30PM	Encaleret Showed Parathyroid Hormone-Independent Normalization of Blood and Urine Calcium in Phase 2 Proof-of-Concept Study in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Sep-05-25 07:00PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Sep-03-25 07:30AM	BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET (GlobeNewswire)
07:03PM	Loading…
Sep-02-25 07:03PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:30AM	BridgeBio to Present Phase 2 Proof-of-Concept Data for Encaleret in Post-Surgical Hypoparathyroidism (GlobeNewswire)
Aug-30-25 07:15AM	Acoramidis Demonstrates Statistically Significant Reduction in Cardiovascular Mortality (CVM) through Month 42 of the ATTRibute-CM Open Label Extension (GlobeNewswire)
Aug-28-25 11:49PM	Here's What Wall Street Thinks About BridgeBio Pharma (BBIO) (Insider Monkey) +6.01%
06:48PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
10:10AM	Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum? (Zacks)
Aug-27-25 07:30AM	BridgeBio to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 07:30AM	BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025 (GlobeNewswire)
Aug-20-25 12:34AM	TD Cowen Reiterates Buy Rating on BridgeBio Pharma (BBIO) on Strong Attruby Sales (Insider Monkey)
Aug-12-25 10:56AM	Skeletal Dysplasia Market Growth Analysis 2025-2030 Featuring BioMarin Pharma, BridgeBio Pharma, Ascendis Pharma, Ipsen, QED Therapeutics and Other Major Players (GlobeNewswire)
02:18PM	Loading…
Aug-06-25 02:18PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research) -8.94%
07:33AM	Helix Acquisition Corp. II Retains More than 60% of Trust Account after Redemptions in connection with Business Combination with BridgeBio Oncology Therapeutics (GlobeNewswire)
07:30AM	Nxera debuts an obesity pipeline; BridgeBio battles Alnylam for market share (BioPharma Dive)
03:29AM	BridgeBio Pharma Inc (BBIO) Q2 2025 Earnings Call Highlights: Record Revenue Surge and ... (GuruFocus.com)
Aug-05-25 05:25PM	BridgeBio Pharma (BBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
04:26PM	BridgeBio Pharma: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio Reports Second Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
Aug-04-25 09:22AM	BridgeBio Pharma Inc (BBIO) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
Jul-31-25 10:00AM	Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-30-25 12:37PM	Biotech Has Been Stalling. 3 Stocks That Could See Healthy Gains. (Barrons.com)
09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-29-25 10:00AM	BridgeBio Pharma (BBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Jul-25-25 11:29PM	Leerink Partners Maintains a Buy on BridgeBio Pharma (BBIO) With a $56 PT (Insider Monkey)
Jul-24-25 11:47PM	Truist Sees Upside in BridgeBio Pharma's (BBIO) ATTR-CM Strategy (Insider Monkey)
Jul-23-25 07:30AM	Novel Human Genetics Evidence Confirms Estimates of Genetic Prevalence, Underdiagnosis, and Potentially Greater Symptom Burden of Gain-of-Function CASR Variants Associated with ADH1 (GlobeNewswire)
07:30AM	Loading…
Jul-22-25 07:30AM	BridgeBio to Host Second Quarter 2025 Financial Results Conference Call on Tuesday, August 5, 2025 at 4:30 pm ET (GlobeNewswire)
Jul-16-25 06:17AM	These 2 Momentum Stocks Got a Bullish Nod Heres Why They Could Reach New Highs (TipRanks)
Jul-14-25 09:32AM	Rivian downgraded, PayPal upgraded: Wall Street's top analyst calls (The Fly)
Jul-09-25 09:39AM	Microsoft upgraded, Instacart initiated: Wall Street's top analyst calls (The Fly) +6.46%
Jul-06-25 04:00AM	BridgeBio Pharma Raises $300M Through Partial European Royalty Monetization for BEYONTTRA (Insider Monkey)
Jul-02-25 10:29AM	BridgeBio (BBIO) Tanks After Selling Beyonttra Royalty Rights (Insider Monkey)
Jun-30-25 07:30AM	BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA European Royalty (GlobeNewswire)
Jun-26-25 07:30AM	BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET (GlobeNewswire)
Jun-25-25 06:01AM	TipRanks Perfect 10 Picks: 2 Top-Scoring Stocks That Are Ticking Every Box (TipRanks)
Jun-24-25 04:25AM	Piper Sandler Reaffirms Overweight Rating on BridgeBio Ahead of Phase 3 CALIBRATE Results (Insider Monkey) +5.39%
Jun-11-25 07:54PM	BridgeBio Pharma, Inc. (BBIO) Price Target Raised to $56 from $53 at H.C. Wainwright (Insider Monkey)
Jun-05-25 08:50AM	BridgeBio price target raised to $42 from $37 at BMO Capital (TipRanks)
Jun-02-25 07:30AM	BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire)
May-23-25 03:21PM	Rocket Cos., Middleby, Diebold Nixdorf, and More Stocks See Action From Activist Investors (Barrons.com)
May-21-25 12:33PM	Bayer Begins Phase I Study on BAY 3670549 in Atrial Fibrillation (Zacks)
04:24AM	BridgeBio's Acoramidis: A Breakthrough in ATTR-CM Treatment (Insider Monkey)
May-20-25 09:40AM	Are Medical Stocks Lagging Alignment Healthcare (ALHC) This Year? (Zacks)
07:30AM	Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM (GlobeNewswire)
May-19-25 12:33PM	Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study (GlobeNewswire)
May-14-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
10:27AM	BridgeBio Pharma doses first asymptomatic subject in study of ATTR prevention drug (Clinical Trials Arena)
06:50AM	Why BridgeBio Pharma, Inc. (BBIO) Declined on Tuesday (Insider Monkey)
May-13-25 09:55AM	Wall Street Analysts Believe BridgeBio Pharma (BBIO) Could Rally 63.87%: Here's is How to Trade (Zacks) -6.78%
07:30AM	First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study (GlobeNewswire)
May-12-25 07:30AM	BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC (GlobeNewswire)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
07:30AM	BridgeBio to Participate in the Bank of America Merrill Lynch Global Healthcare Conference 2025 (GlobeNewswire)
Apr-30-25 09:12PM	Why BridgeBio Pharma, Inc. (BBIO) Surged on Wednesday (Insider Monkey) +5.33%
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
12:31PM	Q1 2025 BridgeBio Pharma Inc Earnings Call (Thomson Reuters StreetEvents)
10:04AM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
07:07AM	BridgeBio sales of new heart drug outstrip expectations (BioPharma Dive)
03:17AM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Apr-29-25 09:43PM	BridgeBio Pharma, Inc. (BBIO) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:30PM	BridgeBio Pharma: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
04:01PM	BridgeBio Reports First Quarter 2025 Financial Results and Business Updates (GlobeNewswire)
11:39AM	BridgeBio Pharma, Inc. (BBIO): Among Billionaire Andreas Halvorsen's Stock Picks With Huge Upside Potential (Insider Monkey)
10:29AM	UK MHRA authorises BridgeBios acoramidis for ATTR-CM (Pharmaceutical Technology)
Apr-28-25 07:18PM	BridgeBio Pharma Inc (BBIO) Q1 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
05:00AM	BEYONTTRA (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved by the UK Medicines and Healthcare Products Regulatory Agency to Treat ATTR-CM (GlobeNewswire)
Apr-23-25 10:01AM	Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Apr-22-25 11:14AM	BridgeBio: Early Signs Point To Blockbuster Revenues (Seeking Alpha)
07:30AM	BridgeBio to Host First Quarter 2025 Financial Results Conference Call on Tuesday, April 29, 2025 at 4:30 pm ET (GlobeNewswire)
Apr-11-25 04:01PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-31-25 10:00AM	Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM (GlobeNewswire)
Mar-29-25 04:12PM	Why BridgeBio Pharma (BBIO) Is Among the Best Mid Cap Biotech Stocks to Buy (Insider Monkey)
Mar-27-25 07:00AM	Beyonttra (acoramidis), the First Near-complete TTR Stabilizer ( 90%), Approved in Japan to Treat ATTR-CM (GlobeNewswire)
Mar-24-25 07:30AM	BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions (GlobeNewswire) +7.05%
Mar-21-25 05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
04:00PM	BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
Mar-17-25 04:01PM	BridgeBio Announces CFO Succession (GlobeNewswire)
Mar-03-25 07:16AM	BridgeBio Oncology and Helix enter definitive merger agreement (Pharmaceutical Technology) -5.42%
Feb-28-25 06:50AM	BridgeBio oncology spinout to go public in blank-check merger (BioPharma Dive)
Feb-26-25 11:56AM	BridgeBio Pharma (BBIO): Among the Best Performing Mid Cap Stocks to Buy According to Analysts (Insider Monkey)
02:49AM	BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt (GlobeNewswire)
Feb-24-25 04:09PM	BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt (GlobeNewswire) -5.24%
Feb-23-25 03:07PM	Why BridgeBio Pharma, Inc. (BBIO) is the Best Performing Pharma Stock So Far in 2025 (Insider Monkey)
Feb-22-25 09:20AM	BridgeBio price target raised to $52 from $49 at Scotiabank (TipRanks)
Feb-21-25 05:13PM	Analyst Report: BridgeBio Pharma, Inc. (Morningstar Research)
Feb-20-25 08:57AM	BridgeBio Pharma Inc (BBIO) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
08:55AM	BridgeBio Pharma (BBIO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:49AM	BridgeBio Pharma: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update (GlobeNewswire)

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Francis Patrick McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MCCORMICK FRANK	Director	Sep 05 '25	Option Exercise	11.92	74,000	882,080	157,275	Sep 08 06:06 PM
MCCORMICK FRANK	Director	Sep 05 '25	Sale	53.16	74,000	3,933,544	83,275	Sep 08 06:06 PM
Kumar Neil	Chief Executive Officer	Sep 05 '25	Sale	53.05	40,000	2,122,047	875,686	Sep 08 06:05 PM
Kumar Neil	Chief Executive Officer	Sep 04 '25	Sale	51.34	40,000	2,053,788	895,686	Sep 08 06:05 PM
FRANK P. MCCORMICK	Director	Sep 05 '25	Proposed Sale	53.14	74,000	3,932,057		Sep 05 04:46 PM
Trimarchi Thomas	President and CFO	Aug 21 '25	Sale	49.48	42,237	2,090,081	421,081	Aug 22 04:58 PM
Kumar Neil	Chief Executive Officer	Aug 20 '25	Sale	48.82	26,156	1,276,927	223,090	Aug 22 04:46 PM
THOMAS TRIMARCHI	Officer	Aug 21 '25	Proposed Sale	49.48	42,237	2,090,077		Aug 21 04:10 PM
NEIL KUMAR	Director	Aug 20 '25	Proposed Sale	48.91	26,156	1,279,290		Aug 20 04:23 PM
Trimarchi Thomas	President and CFO	Aug 18 '25	Sale	50.23	17,353	871,722	463,318	Aug 19 07:40 PM
THOMAS TRIMARCHI	Officer	Aug 18 '25	Proposed Sale	50.23	17,353	871,723		Aug 18 04:03 PM
HOMCY CHARLES J	Director	Aug 08 '25	Sale	46.05	250,000	11,512,443	966,674	Aug 12 07:06 PM
HOMCY CHARLES J	Director	Aug 11 '25	Sale	48.00	50,000	2,400,000	916,674	Aug 12 07:06 PM
Apuli Maricel	Chief Accounting Officer	Aug 07 '25	Sale	45.44	1,000	45,440	141,859	Aug 11 06:29 PM
Kumar Neil	Chief Executive Officer	Aug 08 '25	Sale	46.22	40,000	1,848,828	915,686	Aug 11 06:12 PM
Kumar Neil	Chief Executive Officer	Aug 07 '25	Sale	45.45	40,000	1,818,121	935,686	Aug 11 06:12 PM
CHARLES J HOMCY	Director	Aug 11 '25	Proposed Sale	48.00	50,000	2,400,000		Aug 11 04:17 PM
CHARLES J HOMCY	Director	Aug 08 '25	Proposed Sale	46.05	250,000	11,512,420		Aug 08 05:11 PM
Ellis Andrea	Director	Aug 05 '25	Option Exercise	16.75	17,167	287,547	35,756	Aug 07 04:50 PM
Ellis Andrea	Director	Aug 05 '25	Sale	49.00	17,167	841,183	18,589	Aug 07 04:50 PM
ANDREA ELLIS	Director	Aug 05 '25	Proposed Sale	49.00	17,167	841,183		Aug 05 04:26 PM
Kumar Neil	Chief Executive Officer	Jul 02 '25	Sale	42.73	40,000	1,709,050	955,686	Jul 03 04:30 PM
Kumar Neil	Chief Executive Officer	Jul 01 '25	Sale	42.54	40,000	1,701,400	975,686	Jul 03 04:30 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jun 27 '25	Sale	44.00	3,500,000	154,000,000	18,555,375	Jul 01 07:48 PM
KUMAR HALDEA REVOCABLETRUST U/	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
KUMAR HALDEA FAMILY IRREVOCABL	Director	Jul 01 '25	Proposed Sale	43.18	120,000	5,181,600		Jul 01 04:31 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,418	106,504	7,465	Jun 30 05:51 PM
Valantine Hannah	Director	Jun 26 '25	Sale	44.05	2,289	100,824	398	Jun 30 05:51 PM
MCCORMICK FRANK	Director	Jun 24 '25	Sale	44.23	100,000	4,422,800	879,979	Jun 26 05:08 PM
DENIS VON KAEPPLER IRA ROLLOVE	client's wife is a BoD	Jun 26 '25	Proposed Sale	44.03	1,891	83,261		Jun 26 04:19 PM
HANNAH VALANTINE & DENIS VON K	spouse of bod / bod is joint o	Jun 26 '25	Proposed Sale	44.01	1,542	67,863		Jun 26 04:16 PM
HANNAH A VALANTINE & DENIS VON	Officer	Jun 26 '25	Proposed Sale	44.11	876	38,640		Jun 26 04:14 PM
ERICKA VON KAEPPLER & DENIS VO	account owners are spouse and	Jun 26 '25	Proposed Sale	44.13	398	17,562		Jun 26 04:13 PM
MCCORMICK FRANK	Officer	Jun 24 '25	Proposed Sale	44.23	100,000	4,422,803		Jun 24 05:59 PM
Valantine Hannah	Director	Jun 10 '25	Option Exercise	16.75	4,292	71,891	6,056	Jun 11 05:00 PM
Valantine Hannah	Director	Jun 10 '25	Sale	40.00	4,292	171,680	1,764	Jun 11 05:00 PM
HANNAH A VALANTINE	Director	Jun 10 '25	Proposed Sale	40.00	4,292	171,680		Jun 10 04:01 PM
Kumar Neil	Chief Executive Officer	May 20 '25	Sale	33.40	75,000	2,504,978	4,798,447	May 20 06:06 PM
Kumar Neil	Chief Executive Officer	May 19 '25	Sale	33.33	26,156	871,764	217,404	May 20 06:06 PM
NEIL KUMAR	Director	May 19 '25	Proposed Sale	33.84	26,156	885,119		May 19 04:25 PM
KKR Genetic Disorder L.P.	10% Owner	May 12 '25	Sale	34.20	6,000,000	205,200,000	13,260,971	May 14 05:24 PM
KKR Genetic Disorder L.P.	Affiliate	May 12 '25	Proposed Sale	35.68	6,000,000	214,080,000		May 12 09:46 PM
Apuli Maricel	Chief Accounting Officer	May 02 '25	Sale	38.51	1,026	39,509	147,639	May 06 04:45 PM
Lo Andrew	Director	May 02 '25	Sale	38.50	100,000	3,849,900	105,583	May 06 04:42 PM
Lo Andrew	Director	May 02 '25	Proposed Sale	35.23	100,000	3,523,000		May 02 04:36 PM
Kumar Neil	Chief Executive Officer	Apr 22 '25	Sale	34.11	75,000	2,558,025	4,873,447	Apr 24 04:28 PM
Ellis Andrea	Director	Apr 14 '25	Option Exercise	8.45	10,000	84,500	22,000	Apr 16 05:39 PM
Ellis Andrea	Director	Apr 14 '25	Sale	35.00	10,000	350,000	12,000	Apr 16 05:39 PM
ANDREA ELLIS	Director	Apr 14 '25	Proposed Sale	35.00	10,000	350,000		Apr 14 04:21 PM
Ellis Andrea	Director	Apr 01 '25	Option Exercise	8.45	30,000	253,500	42,000	Apr 03 05:11 PM
Ellis Andrea	Director	Apr 01 '25	Sale	34.05	30,000	1,021,500	12,000	Apr 03 05:11 PM
ANDREA ELLIS	Director	Apr 01 '25	Proposed Sale	34.05	30,000	1,021,500		Apr 02 04:48 PM
Kumar Neil	Chief Executive Officer	Mar 25 '25	Sale	36.87	75,000	2,764,943	4,948,447	Mar 27 04:54 PM
Valantine Hannah	Director	Mar 06 '25	Option Exercise	16.75	12,875	215,656	14,639	Mar 10 04:43 PM
Valantine Hannah	Director	Mar 06 '25	Sale	32.58	12,875	419,500	1,764	Mar 10 04:43 PM
KKR Genetic Disorder L.P.	10% Owner	Mar 05 '25	Sale	32.96	6,000,000	197,760,000	19,260,971	Mar 07 06:09 PM
HANNAH A VALANTINE	Director	Mar 06 '25	Proposed Sale	32.58	12,875	419,500		Mar 06 04:06 PM
KKR Genetic Disorder L.P.	Affiliate	Mar 05 '25	Proposed Sale	34.97	6,000,000	209,820,000		Mar 05 09:09 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Option Exercise	17.00	8,500	144,500	110,964	Feb 27 05:36 PM
STEPHENSON BRIAN C	CFO and Treasurer	Feb 25 '25	Sale	33.19	8,500	282,115	102,464	Feb 27 05:36 PM
Kumar Neil	Chief Executive Officer	Feb 25 '25	Sale	33.57	75,000	2,517,971	5,023,447	Feb 27 05:12 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Feb 25 '25	Proposed Sale	36.25	300,000	10,875,000		Feb 25 04:35 PM
BRIAN STEPHENSON	Officer	Feb 25 '25	Proposed Sale	36.25	34,000	1,232,500		Feb 25 04:34 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Feb 19 '25	Sale	36.16	4,148	149,973	102,464	Feb 19 08:50 PM
Kumar Neil	Chief Executive Officer	Feb 19 '25	Sale	36.14	31,543	1,140,024	211,718	Feb 19 08:48 PM
NEIL KUMAR	Director	Feb 19 '25	Proposed Sale	35.49	31,543	1,119,461		Feb 19 04:31 PM
BRIAN STEPHENSON	Officer	Feb 19 '25	Proposed Sale	35.49	4,148	147,213		Feb 19 04:31 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Proposed Sale	34.90	3,065,616	106,989,998		Jan 31 07:18 PM
VIKING GLOBAL INVESTORS LP	10% Owner	Jan 31 '25	Sale	34.90	3,065,616	106,989,998	22,055,375	Jan 31 07:18 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Option Exercise	17.00	68,000	1,156,000	161,758	Jan 30 06:31 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Jan 28 '25	Sale	36.29	68,000	2,467,761	93,758	Jan 30 06:31 PM
Kumar Neil	Chief Executive Officer	Jan 28 '25	Sale	36.29	326,932	11,863,381	5,371,515	Jan 30 06:29 PM
Kumar Neil	Chief Executive Officer	Jan 29 '25	Sale	36.35	273,068	9,925,269	5,098,447	Jan 30 06:29 PM
KUMAR HALDEA REVOCABLE TRUST U	Director	Jan 28 '25	Proposed Sale	36.67	600,000	22,002,000		Jan 28 04:18 PM
BRIAN STEPHENSON	Officer	Jan 28 '25	Proposed Sale	36.67	68,000	2,493,560		Jan 28 04:18 PM
Satvat Ali J.	Director	Dec 30 '24	Option Exercise	16.22	159,404	2,585,134	159,404	Dec 31 05:52 PM
Kumar Neil	Chief Executive Officer	Nov 19 '24	Sale	22.41	27,389	613,826	4,897,443	Nov 20 08:00 PM
STEPHENSON BRIAN C	Secretary, Treasurer & CFO	Nov 19 '24	Sale	22.41	4,156	93,137	93,758	Nov 20 07:57 PM
BRIAN STEPHENSON	Officer	Nov 19 '24	Proposed Sale	22.35	4,156	92,887		Nov 19 04:28 PM
NEIL KUMAR	Director	Nov 19 '24	Proposed Sale	22.35	27,389	612,144		Nov 19 04:24 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BBIO

BridgeBio Pharma Inc

Upgrade your FINVIZ experience